Cynata Enters Agreement for Strategic Alliance in Japan
Filed with ASX · · 2 pages · English
• AUD$250,000 initial equity investment right in Cynata at a premium to market • Potential further minimum investment of at least AUD$2,250,000 for exclusive 2-year option in Japan and certain other Asian countries • Additional up-front fees, milestone fees and royalties for each therapeutic field • Potential for multi-hundred million dollar revenue stream from Japan and Asia • Commercial developm
Cynata Therapeutics Limited on 6ix
Earlier from Cynata Therapeutics
- Cynata Receives $930k R&D Tax Incentive Refund
- Quarterly Activities Report & Appendix 4C
- CYP Receives Favourable Advice from UK Regulatory Authority
Later from Cynata Therapeutics
- Cynata Announces Landmark Licensing Deal
- Compelling Results from Pre-Clinical Stem Cell Study in GvHD
- Cynata & Regience Extend Entitlement Period
- Decision to Grant Patent for Cymerus MSC Technology in Japan
- CYP Manufactures CT Product-Files Further Patent Application
Follow Cynata Therapeutics into a list and get an email when it puts out news.
Follow Cynata Therapeutics